Genmab — Maj 2020
-
Bristol Myers Squibb and bluebird bioannounced that the companies received a Refusal to File letter from the FDA on bb2121 https://investors.bms.com/iframes/press-releases/press-release-details/2020/Bristol-Myers-Squibb-and-bluebird-bio-Provide-Regulatory-Update-on-Idecabtagene-Vicleucel-ide-cel-bb2121-for-the-Treatment-of-Patients-with-Multiple-Myeloma/default.aspx
-
Bluebird down 8% in premarked!
-
Yes - but here: On May 13, 2020, bluebird bio, Inc. (“bluebird”) and Bristol Myers Squibb Company announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020.
-
Kan vi formode at udsalget af warrants er slut?
-
It will come after closing. But only if management sell the shares.
-
Noget af et comeback, som den er ved at lave
-
Se omsætningen! Den skød i vejret for kort tid siden.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind